Have any questions? 706-721-6582 or cts@augusta.edu
- MORAb-003-011: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
Clinical Trial
MORAb-003-011: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
This research is being done to find out if carboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin (PLD), chemotherapies (anticancer drugs) that are used to treat ovarian cancer, work better alone or when given with an investigational drug called Farletuzumab.
Eligibility Criteria
- Female subjects who are at least 18 years of age at the time of informed consent. Have been treated with debulking surgery and a first-line platinum based chemotherapy regimen. CA 125 less than or equal to 3X ULN (105 U/mL) confirmed within 2 weeks of randomization using a centralized laboratory assay.
RESEARCH. INNOVATION. DISCOVERY.